## ICUI: ICU Medical, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.7% below STRENGTH zone (4.0-10.0%); PEG 1.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-8.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($133.30)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bearish (Bullish: 0, Bearish: 0)

**1. Have ICU Medical Insiders Been Selling Stock?**
- Source: Simply Wall Street | 20251201T081032 | Neutral | Relevance: 100%
- An ICU Medical insider recently sold 20% of their holdings, though another insider made a significant purchase in the last year at a lower price. While there was more insider buying than selling in the past year, the recent sale raises questions. Despite the sale, insiders still own 1.2% of the company, suggesting some alignment with shareholders.

**2. ICU Medical, Inc.'s (NASDAQ:ICUI) Share Price Boosted 27% But Its Business Prospects Need A Lift Too**
- Source: Simply Wall Street | 20251201T041120 | Somewhat-Bearish | Relevance: 100%
- ICU Medical, Inc.'s shares have seen a 27% increase recently, but despite this boost, the company's P/S ratio of 1.6x remains low compared to the Medical Equipment industry. This is attributed to the company's declining revenue growth, which significantly lags behind the industry average. Analysts forecast only 2.8% annual revenue growth for ICU Medical over the next three years, compared to 133% for the rest of the industry, suggesting a less prosperous future and justifying the lower valuation.

**3. ICU Medical, Inc.'s (NASDAQ:ICUI) Share Price Boosted 27% But Its Business Prospects Need A Lift Too**
- Source: Sahm | 20251201T081032 | Somewhat-Bearish | Relevance: 96%
- ICU Medical's shares have gained 27% recently but are still down 9.0% over the last year. The company's P/S ratio of 1.6x is low compared to the Medical Equipment industry, which is attributed to its declining revenue and unpromising growth forecasts. Analysts predict only 2.8% annual revenue growth for ICU Medical over the next three years, significantly lower than the industry's projected 133% expansion.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-07 | Keybanc | $175 | $173 | +1% |
| 2025-11-07 | Piper Sandler | $172 | $153 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-07 | Keybanc | main | Overweight |
| 2025-11-07 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($0.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 14.3% (-1.2%)
- Vanguard Group Inc: 10.6% (-1.3%)
- Janus Henderson Grou: 10.0% (+0.1%)
- Fuller & Thaler Asse: 5.6% (-0.3%)
- JPMORGAN CHASE & CO: 5.5% (+78.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.70 elevated, pricing in significant growth expectations. Forward P/E 18.0x stretched relative to 6% growth. Balance sheet: strong liquidity (2.5x). Analyst sentiment positive (2 raises, avg +7%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.7B |
| Beta | 0.83 |
| 52W Range | $107.00 - $175.51 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.70 |
| Forward P/E | 18.0 |
| Current P/E | 19.1 |
| YoY Growth | 6.0% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from 9.3% to 0.7% (-8.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.3pp (needs >4.0% for momentum thesis). MRS_5 (-2.4%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 60. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.74% (CS: 59) | Neutral |
| RSI_14 | 59.8 | Neutral |
| MACD Histogram | 0.20 | Bullish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.125x | Above |
| vs SMA200 | 1.084x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $144.04
- **Stop Loss:** $133.30 (7.5% risk)
- **Target:** $154.78 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 88
- **Position Value:** $12,675.52
- **Portfolio %:** 12.68%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-26 (Est: $1.69)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $2.03 | +41.6% |
| 2025Q2 | $1.50 | $2.10 | +40.0% |
| 2025Q1 | $1.28 | $1.72 | +34.4% |
| 2024Q4 | $1.48 | $2.11 | +42.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*